The company gained an important position in the US pharmaceuticals market in the 1970s, when it acquired Cutter Laboratories Inc. in 1974 and ... Bayer Cross corporate logo. This was under the ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00.

90.96% of the stock is owned by institutional investors. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...

As part of Vertex’s ongoing commitment to patients, the company has established patient support programs to help ensure that qualified patients can access JOURNAVX. For more information visit ...